Tercica, Inc. Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc., a wholly-owned subsidiary of Ipsen (Euronext: IPN) today announced Phase IIIb clinical trial results demonstrating that Increlex® (mecasermin (rDNA origin) injection) achieved statistically significant dose-dependent first-year height velocity increases in children with Primary IGF-1 Deficiency (Primary IGFD) when administered as a twice-daily injection. A second exploratory study demonstrated that when Increlex® is given as a once-daily regimen in the Primary IGFD population, Increlex® achieved statistically significant dose-dependent first-year height velocity increases. Tercica presented the data from both studies, MS301 and MS308 respectively, along with other data presentations for Increlex® at the 13th International Congress of Endocrinology (ICE) meeting in Rio de Janeiro, Brazil. Increlex® is marketed in the United States and other countries for the treatment of growth failure in children with Severe Primary IGFD using twice-daily injections.